Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06277219 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

A Phase 1 study of Advanced Solid Tumor, sponsored by Latticon Antibody Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
150
Enrollment target
4
Study locations

NCT06277219 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Latticon Antibody Therapeutics. The registered enrollment target is 150 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06277219, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Latticon Antibody Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
4
Study locations

Study Summary

This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG LAT010
  • DRUG LAT010 + ICI

Study Locations (4)

Florida

  • D&H Cancer Research Center - Margate

Utah

  • Huntsman Cancer Institute - Salt Lake City

Shandong

  • Cancer Hospital of Shandong First Medical University - Jinan

Zhejiang

  • The First Affiliated Hospital of Zhejiang University School of Medicine - Hangzhou

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-06-05
Est. Completion 2027-03
Phase Phase 1

Sponsor

Latticon Antibody Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06277219

The ClinicalTrials.gov registry entry for NCT06277219 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The listed sponsor is Latticon Antibody Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which LAT010 is the first listed.

NCT06277219 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Utah, Shandong.

Frequently Asked Questions

What is clinical trial NCT06277219 about?

NCT06277219 is a clinical study titled "A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)". This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalatio...

What is the current status of trial NCT06277219?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2024-06-05. Estimated completion is 2027-03.

What conditions does trial NCT06277219 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06277219?

The interventions under investigation include: LAT010 (DRUG), LAT010 + ICI (DRUG).

Who is sponsoring clinical trial NCT06277219?

This trial is sponsored by Latticon Antibody Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06277219 being conducted?

This trial has 4 study locations across Florida, Utah, Shandong, Zhejiang. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.